SLC29A1 and cancer: Conversely, alterations in solute carrier (SLC) transporters, particularly the downregulation of nucleoside transporters like human equilibrative nucleoside transporter 1 (hENT1), lead to decreased drug uptake, further limiting 5-FU’s access to cancer cells.